Israel covid-19 recommendations vaccine Israel

Pfizer, FDA meet to discuss COVID-19 booster

Reading now: 948
www.cidrap.umn.edu

Today officials from the Food and Drug Administration (FDA) and Pfizer will meet to discuss when and if recipients of the company's mRNA COVID-19 vaccine need a booster dose in the coming months given the emergence of the Delta (B1617.2) variant.

Last week the FDA and the Centers for Disease Control and Prevention (CDC) said so far there is not enough data to recommend a booster, but Pfizer cites small trial results and real-world evidence from Israel that show antibodies produced by the vaccine wane over a period of months and are bolstered with a third dose administered within 12 months of the original vaccine series.

Read more on cidrap.umn.edu
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA